Why Cell Therapies Are Manufactured For One Patient

Cell therapies differ from conventional medicines in a way that shapes everything around them. The product is living material, and in many cases it originates from the person receiving it.

The product cannot be standardised

Conventional drugs are chemically defined and identical between doses, which allows large batches to be made, tested and stored.

A cell therapy consists of living cells whose properties vary with their source, meaning each batch differs from every other.

Release testing therefore checks characteristics such as viability, identity and potency for each individual batch rather than confirming a specification once.

Autologous production starts with collection

Where cells come from the patient, the process begins with collecting them, usually by separating a specific population from circulating blood.

Those cells are transported to a manufacturing facility, modified, expanded in number over days to weeks, tested, and returned for administration.

Every step is specific to that individual, and failure at any point means starting again with a patient whose condition may have progressed in the interval.

The chain of identity is a real constraint

Because the material must return to the person it came from, tracking is critical and cannot rely on ordinary batch numbering.

Facilities implement identity systems following the material continuously, since a mix-up would deliver another person's cells with serious consequences.

This adds logistical complexity that scales with patient numbers rather than being absorbed once, unlike conventional manufacturing. Transport conditions, often involving deep freezing, form part of the same chain.

Donor-derived approaches trade one problem for another

Using cells from a healthy donor would allow batch production and eliminate the wait, which is why considerable effort goes in this direction.

The obstacle is immune rejection in both directions: the recipient may reject the cells, and immune cells in the product may attack recipient tissue.

Genetic modification to remove the relevant surface markers is being pursued, adding manufacturing steps and requiring separate demonstration of safety.

Manufacturing shapes access

The requirement for specialist facilities and trained staff limits where these treatments can be delivered, concentrating them in a small number of centres.

Timelines from collection to administration constrain which patients are suitable, since some conditions progress faster than the process allows.

Whether a specific therapy is appropriate depends on diagnosis, disease stage and prior treatment, which is a decision for a treating specialist rather than a general consideration.